Trial Profile
A Double-blind Randomized-controlled Trial to Assess the Efficacy of Methyl Aminolevulinate + Daylight vs Placebo + Daylight in Patients With Facial Photodamage
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Mar 2015
Price :
$35
*
At a glance
- Drugs Methyl aminolevulinate (Primary)
- Indications Photodamage
- Focus Therapeutic Use
- 05 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 16 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 03 Jul 2014 New trial record